Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential | Semantic Scholar
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Abiraterone (Zytiga): Mechanism of Zytiga
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Abiraterone, CYP17 inhibitor Abiraterone (CB-7598)-Xcessbio Biosciences Inc
Steroid synthesis pathway and aromatization. Abiraterone is a novel... | Download Scientific Diagram
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Abiraterone Acetate | ≥99%(HPLC) | Selleck | P450 (e.g. CYP17) inhibitor
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer | Oncology
CYP17 inhibitors for prostate cancer therapy. - Abstract - Europe PMC
Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation. | Semantic Scholar
CYP17A1 - an overview | ScienceDirect Topics
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. - Abstract - Europe PMC
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
CYP17A1 inhibitor - Wikipedia
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases - ScienceDirect
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective - ScienceDirect
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
